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Abstract
Introduction: The gamma analysis used for quality assurance of a complex radiotherapy
plan examines the dosimetric equivalence between planned and measured dose distri-
butions within some tolerance. This study explores whether the dosimetric difference is
correlated with any radiobiological difference between delivered and planned dose.
Methods: VMAT or IMRT plans optimized for 14 cancer patients were calculated and
delivered to a QA device. Measured dose was compared against planned dose using
2-D gamma analysis. Dose volume histograms (for various patient structures) obtained
by interpolating measured data were compared against the planned ones using a 3-D
gamma analysis. Dose volume histograms were used in the Poisson model to calculate
tumor control probability for the treatment targets and in the Sigmoid dose–response
model to calculate normal tissue complication probability for the organs at risk.
Results: Differences in measured and planned dosimetric data for the patient plans
passing at ≥94.9% rate at 3%/3 mm criteria are not statistically significant. Average 
standard deviation tumor control probabilities based on measured and planned data are
65.84.0% and 67.84.1% for head and neck, and 71.92.7% and 73.33.1% for lung
plans, respectively. The differences in tumor control probabilities obtained from mea-
sured and planned dose are statistically insignificant. However, the differences in normal
tissue complication probabilities for larynx, lungs-GTV, heart, and cord are statistically
significant for the patient plans meeting ≥94.9% passing criterion at 3%/3 mm.
Conclusion: A ≥90% gamma passing criterion at 3%/3 mm cannot assure the radio-
biological equivalence between planned and delivered dose. These results agree
with the published literature demonstrating the inadequacy of the criterion for dosi-
metric QA and suggest for a tighter tolerance.
P A C S
87.45.Qr
K E Y WORD S
3DVH, ArcCheck, dosimetric quality assurance, NTCP, radiobiological QA, TCP
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2017 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Received: 15 April 2017 | Revised: 16 June 2017 | Accepted: 22 June 2017
DOI: 10.1002/acm2.12145
J Appl Clin Med Phys 2017; 18:5:237–244 wileyonlinelibrary.com/journal/jacmp | 237
1 | INTRODUCTION
Treatment plans used in radiation therapy are generally evaluated on
the basis of dose distribution and dose volume parameters. Accuracy
of treatment delivery of complex treatment plans is assured through
a quality assurance (QA) process using ion chambers, films and more
commonly with diode array,1,2 and ion chamber array measure-
ments.3 Measured data are generally compared against planned data
using two-dimensional (2-D) gamma analysis. In reality, treatment
target and organs at risk (OARs) present 3-D geometry, and a 2-D
gamma analysis-based dosimetric comparison may not provide infor-
mation about the criticality of a disagreement. Several studies4–7
have shown that 2-D gamma analysis fails to detect errors in some
cases. Even though detailed analysis is still under investigation,8 dose
volume histogram (DVH)-based dosimetric evaluation can provide
structure-by-structure information and a 3-D gamma analysis can be
a better option for the QA purpose. Validity of DVH-based evalua-
tion of delivered intensity-modulated radiation therapy (IMRT) plans
against the corresponding plans optimized with treatment planning
system (TPS) have been demonstrated using film, ion chamber,9 and
BANG3 gel dosimetry.10 A number of studies show that a DVH-
based 3-D gamma analysis provides more reliable comparison than a
point-by-point per-beam 2-D gamma analysis of IMRT plans.8,11,12
Most of the DVH-based studies were based on measurement
and/or interpolation of 2-D device measured data into 3-D dose dis-
tribution.7,10,11 The DVH comparison studies have shown differences
between planned and measured DVHs as well as differences in mean
doses.10,13 As per the report of Task Group (TG) 65 of American
Association of Physicists in Medicine (AAPM), tumor control proba-
bilities (TCPs) are 2–4 more sensitive with respect to the change in
uniform dose and normal tissue complication probabilities (NTCPs)
are and 4–6 times more sensitive to the change in uniform dose.14
However, none of the above mentioned studies have evaluated
whether radiobiological differences existed in any of the cases. A
growing recognition of the limitation of dose volume parameters in
correlating with biological response has prompted for the use of
radiobiological models for treatment planning15 but QA of all plans is
still performed on the basis of dosimetric comparison alone. Very
recently, an attempt for a radiobiological comparison between deliv-
ered and planned IMRT treatment plans was made using a 2-D QA
device (MapCheck, Sun Nuclear) measured dose.16
Here, we use a cylindrical QA device, ArcCheck, for the measure-
ment and compare the measured data against TPS-calculated
(planned) data using 2-D gamma analysis in SNC PatientTM software.
Application of ArcCheck for patient-specific dosimetric QA12 and
DVH-based plan verification using Sun Nuclear’s 3DVH software
has been experimentally verified elsewhere.17 In this study, DVHs
for various structures were created from the ArcCheck measured
data using 3DVH software and compared against the TPS-planned
DVHs using 3-D gamma analysis. Radiobiological comparison of Arc-
Check measured plans was performed against the corresponding
TPS-optimized volumetric-modulated arc therapy (VMAT) or static
gantry IMRT plans.
2 | MATERIALS AND METHODS
2.A | Patient selection, treatment planning, and
measurement
Fourteen patients treated with IMRT or VMAT were retrospec-
tively selected for this study. Among them, seven were head and
neck (H&N) patients and seven were lung patients. Three of H&N
patients were planned for VMAT and four were planned for
IMRT. Similarly, five of the lung patients were planned for VMAT
and two were planned for IMRT. VMAT plans used two full or
partial arcs while IMRT plans used 7–9 static fields to get optimal
target coverage. Sliding window method was used in all plans.
Computed tomography (CT) simulation was performed in a Philips
Big Bore CT scanner (Philips Medical Systems, Amsterdam,
Netherlands). Vac-Locs and type-S masks (CIVCO Radiotherapy,
Coralville, Iowa) were used for immobilizing lung and H&N
patients, respectively. Varian couch is modeled in our TPS and
was inserted in each treatment plan. H&N mask was included in
the body contour (used for dose calculation) while Vac-Loc was
not included in the body contour. Even though the beam attenua-
tion due to the immobilization devices is minimal, the field
arrangement was optimized to minimize the fraction of the beams
passing through them. The lung plans were optimized with Acuros
XB algorithm and all other plans were optimized with AAA algo-
rithm in Eclipse TPS (Version 11.0.47, Varian Medical Systems,
Palo Alto, CA, USA) using 6 MV beam of a Varian TrueBeam STX
linear accelerator. Dose of 66 Gy was prescribed to gross tumor
volume (GTV) of all H&N patients while 60 Gy and 54 Gy were
prescribed to lymph nodes for a few patients. Five of seven lung
patients were prescribed to 66 Gy and other two were prescribed
to 61.2 and 72 Gy, respectively. The dose grid resolution used
was 1 mm for lung and 2 mm for H&N plans. All the plans were
normalized to cover 95% of target volume by 100% of the pre-
scribed dose while minimizing dose to the surrounding OARs. The
planning objectives in terms of dose constraints to OARs were
the following: maximum dose to the spinal cord 50 Gy, maximum
dose to the brainstem 60 Gy, mean dose to parotids <26 Gy (or
median dose <30 Gy), mean dose to larynx <40 Gy, mean dose to
heart <20 Gy, and mean lung dose <20 Gy and V20 Gy <25% to
the lungs. In few patients, some of the OAR dose constraints
were not met due to the close proximity of infiltration of the
tumor to those OARs. The optimized plan doses were calculated
on ArcCheck images in Eclipse TPS and delivered to the ArcCheck
phantom (Sun Nuclear, Melbourne, FL, USA) with the insert in
place. Cumulative dose was recorded using the SNC Patient soft-
ware version 6.2.1 (Sun Nuclear, Melbourne, FL, USA).
2.B | Dosimetric comparison
Dosimetric comparison between planned and measured data com-
prised of mean and maximum dose to treatment target and few
OARs. For H&N plans, mean dose to GTV, esophagus, larynx,
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parotids, and maximum dose to brainstem and cord were compared
while for lung plans, mean dose to the GTV, heart, esophagus, nor-
mal lung, and maximum dose to the cord were compared.
The measured data were compared against the planned data
using a minimum of 90% pass rate with 2-D gamma criteria of 3 mm
distance to agreement (DTA), 3% dose difference (DD) global1 using
the SNC Patient. A 10% dose threshold and global normalization
was used.
The 3DVH software requires two set of data for comparison.
TPS-optimized patient plan, dose distribution, contoured structures
and planning CT images of each patient, corresponding TPS-calcu-
lated (planned) dose on ArcCheck CT images, and measured data
were imported to 3DVH software version 3.2. The ArcCheck mea-
sured data were then converted into 3-D dosimetric data with
planned dose perturbation (PDP) algorithm8,9 and compared
against original patient data obtained from TPS using the 3-D
gamma analysis (3 mm DTA, 3% DD global). The 3-D gamma anal-
ysis results were compared against the corresponding 2-D gamma
analysis results. DVH data for target and various structures
obtained from 3DVH and TPS (1 cGy bin size) were imported to
MATLAB (The MathWorks, Inc., Natick, MA, USA) for radiobiologi-
cal comparison.
2.C | Radiobiological comparison
DVHs based on measurement and TPS were used in biological mod-
els to calculate TCPs and NTCPs using MATLAB. Conventional frac-
tionation scheme (1.8–2 Gy per fraction) was used for the
calculations.
2.D | TCPs with Poisson model
Clinical target volume (CTV) is the volume of tumor intended to
treat. In our study, GTV included gross tumor and subclinical micro-
scopic disease, and CTV was labeled as GTV. Hence, it is appropriate
to calculate TCP for GTV even though dose is prescribed to planning
target volume (PTV) to incorporate set up error. In this study, TCPs
for H&N and lung GTVs were calculated using the Poisson model,18–20
which is expressed in eq. (1).
TCP ¼ 1
2
 P
i
viexp 2c50 1 DiD50
 
=ln2
n o
(1)
Here, D50 is dose yielding 50% probability for tumor control and
c50 is slope of the dose–response curve at the level of 50% TCP.
Similarly, Di and vi are the dose and volume elements of DVHs,
respectively.
For the calculation purpose, 63.43 Gy and 51.24 Gy were used
as D50 for H&N GTV and lung GTV, respectively. Similarly, the val-
ues of 2.66 and 0.83 were used, respectively, for c50. These values
were derived from clinical data (DVHs and treatment outcomes)
using a cohort of 90 patients. A regression analysis was used to fit
the TCP model into the clinical data.21
2.E | NTCP with sigmoid dose–response model
The values of NTCP for various OARs were calculated using DVHs
obtained from planned and measured data in the sigmoid dose–
response (SDR) model,21–23 expressed in eq. 2.
NTCP ¼ U EUD D50
mD50
 
(2)
Here, Φ is the probit function defined by:
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Here, x = (EUD – D50)/mD50, where D50 is the dose yielding 50%
NTCP, obtained from dose–response curve, and EUD is equivalent uni-
form dose, defined as the dose which distributed uniformly over a
structure would produce the same effect as the dose specified by the
DVH. The parameter m represents the slope of the dose–response
curve. EUD is also defined as a generalized equivalent uniform dose
(gEUD) calculated using the series of dose volume pairs (Di. vi), obtained
from the DVH of a structure using the formula expressed in eq. 4.
gEUD ¼
X
i
viD
1=n
i
" #n
(4)
Here, n is a parameter that determines the dose volume depen-
dence of a given OAR.
Brainstem, spinal cord, esophagus, larynx, and left parotid and
right parotid NTCPs were evaluated for H&N plans while bilateral
lungs, heart, spinal cord, and esophagus NTCPs were evaluated for
lung patients. D50, n, and m values from Burman et al.
22,24 used for
NTCP calculations are tabulated in Table 1.
2.F | Statistical analysis
The Shapiro–Wilk test was used to test the normality of the data. A
two-tailed Student t-test (0.05 significance level) was performed for
the data following normal distribution to test the significance in dif-
ference between (a) planned and measured dose to the studied
structures, (b) 2-D and 3-D gamma analysis results, (c) TCPs based
on planned and measured data, and (d) NTCPs based on planned
and measured data. Wilcoxon signed rank test was performed on
the data not following a normal distribution.
2.G | Effect of tighter tolerance on dosimetric
analysis
Tighter tolerances of 2.5%/2.5 mm and 2%/2 mm global normaliza-
tion were used for 2-D gamma analysis to check whether a radiobio-
logical equivalence between planned and delivered dose distributions
exists for the patient plans passing at ≥90%.
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3 | RESULTS
3.A | Dosimetric comparison
Mean and maximum doses to GTV and various OARs for H&N and
lung patients are tabulated in Tables 2 and 3, respectively. Also the
p-values of the statistical test between planned and measured dose
for each structure are included in the tables.
As signified by the P-values of statistical test tabulated in
Tables 2 and 3, the differences between planned and measured dose
are not statistically significant at 0.05 significant level for any of the
structures studied.
Similarly, the results of 2-D and 3-D gamma analysis are com-
pared in Figures 1 and 2.
The differences in 2-D and 3-D gamma passing rates ranged
between 0% and 2.7% for H&N patient plans with a mean difference
of 0.1% while they ranged between 0.1% and 4.5% for lung patient
plans with a mean difference of 0.5%. However, a statistical test
performed on both H&N and lung patient plans showed no signifi-
cant differences between 2-D and 3-D gamma analysis results at
95% confidence level. P-values of the test were >0.05 for both H&N
and lung patient plans.
A DVH comparison based on planned and measured data for a
patient (patient 2, Figure 2) plan is presented in Figure 3.
3.B | Radiobiological comparison
3.B.1 | TCP comparison
Mean and standard deviation (SD) of TCPs for patient plans, and
P-values of statistical test between the dataset based on plan and
measurement are tabulated in Tables 4 and 5.
As evident from Tables 4 and 5, the differences between two
set of TCPs are statistically insignificant for H&N as well lung
patients plans.
3.B.2 | NTCP comparison
The EUDs to majority of the OARs calculated based on the planned
DVHs and measured data were close to each other and the differ-
ences were insignificant for majority of H&N as well as lung patient
OARs. However, the differences were significant in few cases. There
was a significant difference in NTCPs for larynx in H&N patients and
for lungs-GTV, cord, and heart in lung patients. NTCPs from planned
TAB L E 1 D50, m, and n values used to calculate NTCPs.
Structure Larynx Esophagus Parotids Brainstem Cord Bilat. lungs Heart
D50 (Gy) 70.0 68.0 46.0 65.0 66.5 24.5 48.0
m 0.17 0.11 0.18 0.14 0.17 0.18 0.10
n 0.08 0.06 0.70 0.16 0.05 0.87 0.35
TAB L E 2 Mean or maximum dose (Gy) to various structures obtained from treatment plan and measurement, and P-values of statistical test
for H&N patient plans.
Patient No.
Mean dose (Gy)
Lt Parotid Rt Parotid
Maximum dose (Gy)
GTV Larynx Esophagus Brainstem Cord
1 Planned 67.8 47.6 30.0 28.9 27.5 23.4 45.8
Measured 69.4 48.4 30.3 29.2 27.5 22.4 46.0
2 Planned 65.4 32.3 36.7 25.0 27.8 29.3 30.9
Measured 66.0 32.7 36.6 25.5 28.3 29.7 31.3
3 Planned 67.4 38.8 31.9 25.9 23.7 39.8 46.6
Measured 69.1 39.7 32.6 26.3 24.1 41.1 47.5
4 Planned 67.5 37.4 1.0 62.0 21.8 24.8 12.6
Measured 67.2 37.6 1.0 61.2 21.6 24.9 12.2
5 Planned 68.7 7.5 0.4 1.4 1.2 0.6 20.0
Measured 68.8 8.1 0.4 1.5 1.3 0.7 10.8
6 Planned 68.0 64.6 10.9 28.5 29.1 23.2 50.4
Measured 68.8 66.5 11.0 28.4 29.1 23.4 46.2
7 Planned 69.1 40.2 34.1 25.3 32.5 50.7 47.8
Measured 69.1 40.7 34.1 24.9 32.2 51.2 48.5
Average  SD Planned 67.7  1.2 38.3  17.2 20.7  16.0 28.1  17.7 23.4  10.4 27.4  15.6 36.3  15.2
Measured 68.3  1.3 39.1  17.5 20.9  16.1 28.1  17.4 23.4  10.4 27.6  15.9 34.6  16.8
P-value >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
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and measured data as well as P-values of the statistical test for the
studied OARs are tabulated in Tables 6 and 7, respectively. The
structures with significant difference in NTCPs are marked bold.
NTCPs for the other OARs in most of the studied patients were
negligible, ranging between 107% and less than a percent. Only the
values greater than or equal to 0.5% have been tabulated to one sig-
nificant figure in Tables 6 and 7, and all values smaller than 0.5%
have been indexed as <0.5%.
As evident from Tables 6 and 7, differences in NTCPs based on
measurement and calculation are statistically significant for larynx,
lungs-GTV, heart, and cord. Even though the values are a few
percent, the statistically significant difference in NTCPs may indicate
a possibility of clinically significant difference between delivered and
intended outcome.
3.C | Effect of tighter tolerance on dosimetric
gamma analysis
A 2-D gamma analysis performed at 2.5%/2.5 mm reduced the pass
rate slightly for most of the patient plans but not below 92.7% for
any of the plans. The pass rate ranged between 92.7% and 100.0%
with median pass rate of 99.4% for H&N plans and between 91.0%
TAB L E 3 Mean or maximum dose (Gy) to various structures obtained from treatment plan and measurement, and p-values of statistical test
for lung patient plans.
Patient No. Dose (Gy) GTVmean Heartmean Cordmax Esophagusmean Lungmean
1 Planned 67.6 13.9 40.9 21 18.9
Measured 69.6 14.6 41.9 21.7 19.6
2 Planned 63.4 3.4 39.1 19.7 16.2
Measured 63.9 3.5 39.5 19.9 16.4
3 Planned 68.1 0.3 28.1 3.3 3.5
Measured 67.3 0.3 29 3.4 3.6
4 Planned 67.8 8.7 43.4 29.8 16.3
Measured 69.3 8.8 44.4 29.8 16.9
5 Planned 70.2 1.7 43.7 6.7 13.3
Measured 73 1.8 47 6.7 13.8
6 Planned 64.8 4.7 37 15.7 13.2
Measured 66.3 4.8 37.4 15.8 13.6
7 Planned 69.2 1.2 36.8 16.2 8.5
Measured 70.6 1.2 37.3 16.6 8.8
Average SD Planned 67.3  2.4 4.8  4.9 38.4  5.3 16.1  8.9 12.8  5.3
Measured 68.6  3.0 5.0  5.1 39.5  5.9 16.3  9.0 13.2  5.4
P-value >0.05 >0.05 >0.05 >0.05 >0.05
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and 99.5% with median pass rate of 96.6% for lung plans. However,
for a 2-D gamma analysis based on 2%/2 mm criterion, pass rate for
H&N patients ranged between 85.3% and 99.6% with the median
pass rate of 98.3%. For lung patient plans, it ranged between 83.3%
and 97.1% with the median pass rate of 90.2%. Only five H&N
patient plans and three lung patient plans met the passing criterion
of ≥90% at 2%/2 mm. The statistical test on the plans passing by
≥90% at 2%/2 mm criterion did not show any radiobiological differ-
ence for any of the structures studied.
4 | DISCUSSION
Our study showed small dosimetric differences between 2-D and
3-D gamma analysis results, which are in line with the results
obtained by Infusino et al.17 using ArcCheck for the measurement.
However, our radiobiological comparisons do not agree with the
results from Sumida et al.16 where the TCPs based on measured data
were found to be significantly smaller and NTCPs to be significantly
higher than the ones based on planned data. Possible differences
could be because of differences in device type, geometry, differences
in measurement and analysis techniques, as well as the different radio-
biological models used to calculate TCPs and NTCPs. While Sumida
et al. had used per-beam analysis using MapCheck measured data, we
have used cumulative dose analysis using ArcCheck measured data.
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TAB L E 4 TCPs and statistical values from planned and measured data for H&N patients.
Patient No. 1 2 3 4 5 6 7 Mean SD P-value
TCP (%) Planned 57.9 64.7 65.0 66.5 67.0 69.2 70.1 65.8 4.0 >0.05
Measured 60.2 63.8 70.3 71.2 69.5 69.6 70.0 67.8 4.1
TAB L E 5 TCPs and statistical values from planned and measured data for lung patients.
Patient No. 1 2 3 4 5 6 7 Mean SD P-value
TCP (%) Planned 67.5 69.1 72.4 72.7 72.9 74.1 74.9 71.9 2.7 >0.05
Measured 68.2 70.8 74.5 74.2 72.1 75.5 77.6 73.3 3.1
TAB L E 6 NTCPs from planned and measured data for H&N patient OARs and P-values of statistical test.
Structure NTCP (%)
Patient No.
Average  SD P-value1 2 3 4 5 6 7
Brainstem Planned <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5  <0.5 >0.05
Measured <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5  <0.5
Cord Planned 1.6 1.1 0.7 <0.5 <0.5 <0.5 <0.5 0.5  0.6 >0.05
Measured 1.7 1.3 0.8 1.1 <0.5 <0.5 <0.5 0.7  0.7
Esophag. Planned 0.7 1.5 <0.5 <0.5 <0.5 <0.5 < 0.5 0.5  0.6 >0.05
Measured 0.8 1.8 <0.5 <0.5 <0.5 <0.5 < 0.5 0.5  0.6
Larynx Planned 2.0 3.8 37.1 0.9 <0.5 <0.5 14.7 8.4  13.6 <0.05
Measured 2.4 4.4 44.4 1.2 <0.5 <0.5 15.8 9.8  16.2
Lt Parotid Planned 1.1 <0.5 <0.5 <0.5 1.2 <0.5 56.7 8.5  21.3 >0.05
Measured 0.9 <0.5 <0.5 <0.5 1.4 <0.5 52.0 7.8  19.5
Rt Parotid Planned 9.2 <0.5 <0.5 <0.5 2.7 <0.5 < 0.5 1.7  3.4 >0.05
Measured 8.6 <0.5 <0.5 <0.5 3.1 <0.5 < 0.5 2.5  4.0
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Due to nonzero detecting threshold of detectors used in the measure-
ment, per-beam analysis suppresses low dose for every beam data
while with the cumulative analysis, low doses from multiple beams can
add up to be detectable enough by the detectors. Also ArcCheck mea-
sures both entrance and exit doses essentially doubling the detector
density while Mapcheck measures only the entrance dose. Sumida
et al. had used voxel-based Niemierko’s model to calculate TCPs and
NTCPs but we have used Poisson model for TCP calculation and SDR
model for NTCP calculation. The other difference is that the study is
based on structure-by-structure gamma analysis but we have per-
formed overall gamma analysis. However, the D50 and c50 values used
to calculate TCPs for H&N patients in our study match with the values
used in the study.
The accuracy of ArcCheck measurement and PDP algorithm is
out of scope of this study. Study by Sun Nuclear Corporation shows
an excellent accuracy of PDP25 and the algorithm has been applied
in a number of independent studies8–12 before and validated against
ion chamber, diode array, and gel dosimetry.
AAPM TG 119 recommends a passing criteria of 90% with 3%/
3 mm DTA for per-beam analysis and 88%–90% for composite dose
analyzed with radiographic films. The minimum pass rate in our study
was 94.9% at 3%/3 mm DTA for composite analysis. In spite of 94.9%
minimum pass rate, the differences in NTCPs based on planned and
measured data for few of the structures studied were statistically sig-
nificant. However, for the patients with passing rate of ≥90% at 2%/
2 mm, no statistically significant radiobiological difference was
observed for any of the structures. As the number of patient plans
passing by ≥90% at 2%/2 mm is small, it may not be a wise idea to gen-
eralize these results and hence a study on a large number of patients is
required to determine whether 90% gamma passing rate at 2%/2 mm
is sufficient for radiobiological assurance. However, our results demon-
strating a statistically significant radiobiological difference for the
patient plans meeting ≥94.9% pass rate at 3%/3 mm cohere with the
inadequacy of 3%/3 mm gamma analysis criterion as discussed by Cad-
man,26 demonstrated by Nelms et al.12 and outlined by AAPMMedical
Physics Practice Guideline 5.a.27 Our future study will focus on finding
the tolerance criteria for the radiobiological quality assurance.
Another point worth mentioning is that the dosimetric or biologi-
cal pass rate was not favored by any of the IMRT or VMAT
modality. Although this finding is clear in our dataset, generalizing
this argument is not in the scope of this study. The investigation of
this topic would require a study of a different design, where other
elements of the plans such as the level of beam modulation, etc.,
would be thoroughly studied.
5 | CONCLUSIONS
Differences between 2-D and 3-D gamma analysis results for H&N
and lung patients are small and statistically insignificant. The differ-
ences between TCPs obtained from the planned and measured data
are also small and insignificant. However, the differences in NTCPs
based on planned and measured data for a few of the structures
studied are statistically significant even though the dosimetric
agreements are ≥94.9% at 3%/3 mm DTA. Our study based on
14 patients suggests that ≤94.9% pass rate at 3%/3 mm DTA used
for 2-D or 3-D gamma analysis cannot assure the radiobiological
equivalence between a delivered and the corresponding planned
dose. Hence, radiobiological analysis in addition to dosimetric com-
parison may have to be considered for the QA of complex radio-
therapy plans.
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